-
胰腺癌是一种恶性程度高、易转移、进展快、预后差的恶性肿瘤,是全球因癌症死亡的第七大病因,患者的5年生存率仅为9%,其唯一有希望治愈的方法是根治性手术切除[1-3]。然而,只有20%的胰腺癌患者有手术治疗的机会,超过50%的患者在初诊时就发现了远处转移灶[1, 3]。为了选择最合适的治疗方法(如手术切除、手术后的新辅助治疗或姑息治疗),早期诊断、准确分期和及时的疗效评估对胰腺癌患者至关重要[3-4],而在这些过程中,影像学方法发挥着无可替代的重要作用。
近年来,一体化的PET/MRI作为一种新型的将PET和MRI有机整合的多模态成像系统,实现了2种不同设备在相同空间内对各自数据的同时采集,兼具各设备的独立功能,既结合了MRI的高软组织分辨率与多参数、多功能成像特性,又结合了PET的放射性示踪剂代谢高灵敏度以及数据定量化特性[5],因此,PET/MRI在反映解剖学结构形态和生理学功能信息方面具有独特优势。PET/MRI现已被用于全身多种肿瘤诊断和治疗方面的研究,在胰腺癌中的应用也崭露头角。因此,我们就18F-FDG PET/MRI的优势及其在胰腺癌诊断和治疗中的应用及新进展综述如下。
18F-FDG PET/MRI在胰腺癌中的临床应用及新进展
Clinical application and new progress of 18F-FDG PET/MRI in pancreatic cancer
-
摘要: 胰腺癌是一种恶性程度高、易转移、进展快、预后差的恶性肿瘤,早期诊断、准确分期和及时的疗效评估对胰腺癌患者至关重要。一体化的PET/MRI作为一种新型的多模态成像技术,集合了MRI对软组织分辨率高、多序列、多参数和PET代谢显像的高灵敏度等优势,在胰腺癌患者的肿瘤分期、疗效评估、预后预测、复发监测等方面具有潜在的应用价值。因此,笔者就18F-氟脱氧葡萄糖(FDG)PET/MRI的优势及其在胰腺癌中的临床应用及新进展进行综述。
-
关键词:
- 胰腺肿瘤 /
- 正电子发射断层显像术 /
- 磁共振成像 /
- 氟脱氧葡萄糖F18
Abstract: Pancreatic cancer is a malignant tumor with high malignant degree, easy metastasis, rapid progression and poor prognosis, so early diagnosis, accurate staging and timely efficacy evaluation are crucial for patients with pancreatic cancer. As a novel multimodality imaging technology, integrated PET/MRI combines with high resolution for soft-tissue, multi-sequences, multi-parameters of MRI and high sensitivity of PET metabolic imaging, it has potential application value in tumor staging, efficacy evaluation, prognosis prediction, and recurrence monitoring of pancreatic cancer patients. Therefore, this paper reviews the advantages of 18F-fluorodeoxyglucose (FDG) PET/MRI and its clinical application and new progress in pancreatic cancer. -
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7−30. DOI: 10.3322/caac.21590. [2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394−424. DOI: 10.3322/caac.21492. [3] Lau SC, Cheung WY. Evolving treatment landscape for early and advanced pancreatic cancer[J/OL]. World J Gastrointest Oncol, 2017, 9(7): 281−292[2021-03-27]. https://www.wjgnet.com/1948-5204/full/v9/i7/281.htm. DOI: 10.4251/wjgo.v9.i7.281. [4] Lee JW, O JH, Choi M, et al. Impact of 18F-fluorodeoxyglucose PET/CT and PET/MRI on initial staging and changes in management of pancreatic ductal adenocarcinoma: a systemic review and meta-analysis[J/OL]. Diagnostics (Basel), 2020, 10(11): 952[2021-03-27]. https://www.mdpi.com/2075-4418/10/11/952. DOI: 10.3390/diagnostics10110952. [5] Quick HH. Integrated PET/MR[J]. J Magn Reson Imaging, 2014, 39(2): 243−258. DOI: 10.1002/jmri.24523. [6] Broski SM, Goenka AH, Kemp BJ, et al. Clinical PET/MRI: 2018 update[J]. AJR Am J Roentgenol, 2018, 211(2): 295−313. DOI: 10.2214/ajr.18.20001. [7] Ward RD, Amorim B, Li WE, et al. Abdominal and pelvic 18F-FDG PET/MR: a review of current and emerging oncologic applications[J]. Abdom Radiol (NY), 2021, 46(3): 1236−1248. DOI: 10.1007/s00261-020-02766-2. [8] 曾天翼, 宋少莉, 吕力琅. 一体化PET/MR技术的发展及临床应用[J]. 肿瘤影像学, 2019, 28(4): 276−282. DOI: 10.19732/j.cnki.2096-6210.2019.04.013.
Zeng TY, Song SL, Lyu LL. Technical progress and clinical application of integrated PET/MR[J]. Oncoradiology, 2019, 28(4): 276−282. DOI: 10.19732/j.cnki.2096-6210.2019.04.013.[9] Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications[J]. Radiology, 2013, 267(1): 26−44. DOI: 10.1148/radiol.13121038. [10] Tatsumi M, Isohashi K, Onishi H, et al. 18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT[J]. Int J Clin Oncol, 2011, 16(4): 408−415. DOI: 10.1007/s10147-011-0202-x. [11] Nagamachi S, Nishii R, Wakamatsu H, et al. The usefulness of 18F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with 18F-FDG PET/CT[J]. Ann Nucl Med, 2013, 27(6): 554−563. DOI: 10.1007/s12149-013-0719-3. [12] Chen BB, Tien YW, Chang MC, et al. PET/MRI in pancreatic and periampullary cancer: correlating diffusion-weighted imaging, MR spectroscopy and glucose metabolic activity with clinical stage and prognosis[J]. Eur J Nucl Med Mol Imaging, 2016, 43(10): 1753−1764. DOI: 10.1007/s00259-016-3356-y. [13] Joo I, Lee JM, Lee DH, et al. Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study[J]. Radiology, 2017, 282(1): 149−159. DOI: 10.1148/radiol.2016152798. [14] 郝利国, 崔红升, 孟鑫, 等. PET/MRI检查技术评估胰腺癌肿瘤可切除性的应用研究[J]. 临床放射学杂志, 2017, 36(8): 1129−1133. DOI: 10.13437/j.cnki.jcr.2017.08.020.
Hao LG, Cui HS, Meng X, et al. The value of resectability of pancreatic cancer by PET/MR[J]. J Clin Radiol, 2017, 36(8): 1129−1133. DOI: 10.13437/j.cnki.jcr.2017.08.020.[15] Furtado FS, Ferrone CR, Lee SI, et al. Impact of PET/MRI in the treatment of pancreatic adenocarcinoma: a retrospective cohort study[J]. Mol Imaging Biol, 2021, 23(3): 456−466. DOI: 10.1007/s11307-020-01569-7. [16] Wang XY, Yang F, Jin C, et al. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer[J]. World J Gastroenterol, 2014, 20(42): 15580−15589. DOI: 10.3748/wjg.v20.i42.15580. [17] Pakzad F, Groves AM, Ell PJ. The role of positron emission tomography in the management of pancreatic cancer[J]. Semin Nucl Med, 2006, 36(3): 248−256. DOI: 10.1053/j.semnuclmed.2006.03.005. [18] Sahani DV, Bonaffini PA, Catalano OA, et al. State-of-the-art PET/CT of the pancreas: current role and emerging indications[J]. Radiographics, 2012, 32(4): 1133−1158. DOI: 10.1148/rg.324115143. [19] Izuishi K, Yamamoto Y, Sano T, et al. Impact of 18-fluoro-deoxyglucose positron emission tomography on the management of pancreatic cancer[J]. J Gastrointest Surg, 2010, 14(7): 1151−1158. DOI: 10.1007/s11605-010-1207-x. [20] Lytras D, Connor S, Bosonnet L, et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer[J]. Dig Surg, 2005, 22(1/2): 55−61. DOI: 10.1159/000085347. [21] Farma JM, Santillan AA, Melis M, et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms[J]. Ann Surg Oncol, 2008, 15(9): 2465−2471. DOI: 10.1245/s10434-008-9992-0. [22] Gao J, Huang XY, Meng HP, et al. Performance of multiparametric functional imaging and texture analysis in predicting synchronous metastatic disease in pancreatic ductal adenocarcinoma patients by hybrid PET/MR: initial experience[J/OL]. Front Oncol, 2020, 10: 198[2021-03-27]. https://www.frontiersin.org/articles/10.3389/fonc.2020.00198/full. DOI: 10.3389/fonc.2020.00198. [23] Katz MHG, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators[J]. Cancer, 2012, 118(23): 5749−5756. DOI: 10.1002/cncr.27636. [24] Panda A, Garg I, Truty MJ, et al. Borderline resectable and locally advanced pancreatic cancer: FDG PET/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival[J]. AJR Am J Roentgenol, 2021, 217(3): 730−740. DOI: 10.2214/ajr.20.24567. [25] Wang ZJ, Behr S, Consunji MV, et al. Early response assessment in pancreatic ductal adenocarcinoma through integrated PET/MRI[J]. AJR Am J Roentgenol, 2018, 211(5): 1010−1019. DOI: 10.2214/ajr.18.19602. [26] Chen BB, Tien YW, Chang MC, et al. Multiparametric PET/MR imaging biomarkers are associated with overall survival in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2018, 45(7): 1205−1217. DOI: 10.1007/s00259-018-3960-0. [27] Dunet V, Halkic N, Sempoux C, et al. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma[J]. Eur Radiol, 2021, 31(2): 992−1001. DOI: 10.1007/s00330-020-07191-z. [28] Sperti C, Pasquali C, Bissoli S, et al. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT[J]. J Gastrointest Surg, 2010, 14(1): 131−140. DOI: 10.1007/s11605-009-1010-8. [29] Ruf J, Hänninen EL, Oettle H, et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI[J]. Pancreatology, 2005, 5(2/3): 266−272. DOI: 10.1159/000085281.
计量
- 文章访问数: 3488
- HTML全文浏览量: 2573
- PDF下载量: 25